Cargando…

Increased plasma sVCAM-1 is associated with severity in IgA nephropathy

BACKGROUND: A considerable proportion of IgAN patients present with histological vasculitic/crescentic lesions in glomeruli, indicating activation of vascular inflammation. Using sVCAM-1, a well-proven marker for endothelial injury under inflammatory processes, we investigated vascular injury and it...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Li, Shi, Sufang, Liu, Lijun, Lv, Jicheng, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557193/
https://www.ncbi.nlm.nih.gov/pubmed/23336423
http://dx.doi.org/10.1186/1471-2369-14-21
_version_ 1782257280830406656
author Zhu, Li
Shi, Sufang
Liu, Lijun
Lv, Jicheng
Zhang, Hong
author_facet Zhu, Li
Shi, Sufang
Liu, Lijun
Lv, Jicheng
Zhang, Hong
author_sort Zhu, Li
collection PubMed
description BACKGROUND: A considerable proportion of IgAN patients present with histological vasculitic/crescentic lesions in glomeruli, indicating activation of vascular inflammation. Using sVCAM-1, a well-proven marker for endothelial injury under inflammatory processes, we investigated vascular injury and its association with clinical and pathological manifestations in IgAN patients. METHODS: In this study, 327 biopsy-proven IgAN patients and 55 healthy controls were enrolled. The Oxford classification and two variables, Active Crescentic Lesion Percentage (ACLP) and Chronic Glomerular Lesion Percentage (CGLP), were used for evaluating pathological lesions. Human Umbilical Vein Endothelial Cells were treated with 25-400 ug/ml IgA1. sVCAM-1 in plasma and culture supernatant were measured by ELISA. RESULTS: Plasma sVCAM-1 in IgAN patients was significantly higher than healthy controls. In patients with IgAN, plasma sVCAM-1 was significantly correlated with eGFR, 24h urine protein excretion, tubular atrophy/interstitial fibrosis lesion and ACLP, but not CGLP. Meanwhile, compared to healthy volunteers, IgA1 from IgAN patients showed a tendency to increase the HUVECs supernatant sVCAM-1 expression. And IgA1 induced the sVCAM-1 increasing from HUVECs in time- and dose-dependent manner. CONCLUSIONS: We found increased plasma sVCAM-1 in IgAN patients and its association with severe clinical and pathological manifestations, which might be partly resulted from effect of IgA1 to endothelial cells.
format Online
Article
Text
id pubmed-3557193
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35571932013-01-31 Increased plasma sVCAM-1 is associated with severity in IgA nephropathy Zhu, Li Shi, Sufang Liu, Lijun Lv, Jicheng Zhang, Hong BMC Nephrol Research Article BACKGROUND: A considerable proportion of IgAN patients present with histological vasculitic/crescentic lesions in glomeruli, indicating activation of vascular inflammation. Using sVCAM-1, a well-proven marker for endothelial injury under inflammatory processes, we investigated vascular injury and its association with clinical and pathological manifestations in IgAN patients. METHODS: In this study, 327 biopsy-proven IgAN patients and 55 healthy controls were enrolled. The Oxford classification and two variables, Active Crescentic Lesion Percentage (ACLP) and Chronic Glomerular Lesion Percentage (CGLP), were used for evaluating pathological lesions. Human Umbilical Vein Endothelial Cells were treated with 25-400 ug/ml IgA1. sVCAM-1 in plasma and culture supernatant were measured by ELISA. RESULTS: Plasma sVCAM-1 in IgAN patients was significantly higher than healthy controls. In patients with IgAN, plasma sVCAM-1 was significantly correlated with eGFR, 24h urine protein excretion, tubular atrophy/interstitial fibrosis lesion and ACLP, but not CGLP. Meanwhile, compared to healthy volunteers, IgA1 from IgAN patients showed a tendency to increase the HUVECs supernatant sVCAM-1 expression. And IgA1 induced the sVCAM-1 increasing from HUVECs in time- and dose-dependent manner. CONCLUSIONS: We found increased plasma sVCAM-1 in IgAN patients and its association with severe clinical and pathological manifestations, which might be partly resulted from effect of IgA1 to endothelial cells. BioMed Central 2013-01-22 /pmc/articles/PMC3557193/ /pubmed/23336423 http://dx.doi.org/10.1186/1471-2369-14-21 Text en Copyright ©2013 Zhu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhu, Li
Shi, Sufang
Liu, Lijun
Lv, Jicheng
Zhang, Hong
Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
title Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
title_full Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
title_fullStr Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
title_full_unstemmed Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
title_short Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
title_sort increased plasma svcam-1 is associated with severity in iga nephropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557193/
https://www.ncbi.nlm.nih.gov/pubmed/23336423
http://dx.doi.org/10.1186/1471-2369-14-21
work_keys_str_mv AT zhuli increasedplasmasvcam1isassociatedwithseverityiniganephropathy
AT shisufang increasedplasmasvcam1isassociatedwithseverityiniganephropathy
AT liulijun increasedplasmasvcam1isassociatedwithseverityiniganephropathy
AT lvjicheng increasedplasmasvcam1isassociatedwithseverityiniganephropathy
AT zhanghong increasedplasmasvcam1isassociatedwithseverityiniganephropathy